FDA HAS ASSIGNED RMAT STATUS TO RETT SYNDROME GENE THERAPY
For citations:
FDA HAS ASSIGNED RMAT STATUS TO RETT SYNDROME GENE THERAPY. Pediatric pharmacology. 2024;21(3):296. (In Russ.)
Views:
185
Popular articles
Vol 16, No 1 (2019)
Vol 12, No 6 (2015)
Vol 11, No 4 (2014)
Vol 7, No 5 (2010)
Vol 13, No 4 (2016)
Article Tools
Email this article (Login required)
Email the author (Login required)
Email this article (Login required)
Email the author (Login required) "Paediatrician" Publishers LLC
Unit 4/1, 54–4 Vavilova Street, 119296, Moscow, Russian Federation
Web-site: www.spr-journal.ru
E-mail: pedpharm@spr-journal.ru, redactorspr@spr-journal.ru
Tel.: +7 (499) 132-02-17
Mob.: +7 (916) 650-07-42
